Eli Lilly Company News

Eli Lilly and QurCan sign genetic medicine deal - Pharmaceutical Technology

Eli Lilly and QurCan sign genetic medicine deal Pharmaceutical Technology

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health - PR Newswire

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health PR Newswire

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It Yahoo Finance

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs - Reuters

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs Reuters

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases - businesswire.com

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases businesswire.com

Eli Lilly has more than 30% of new patients on oral weight-loss meds: exec - Seeking Alpha

Eli Lilly has more than 30% of new patients on oral weight-loss meds: exec Seeking Alpha

Eli Lilly lawsuit against weight-loss drug seller gets another shave - Courthouse News

Eli Lilly lawsuit against weight-loss drug seller gets another shave Courthouse News

Great News for Eli Lilly Stock Investors - The Motley Fool

Great News for Eli Lilly Stock Investors The Motley Fool

Berenberg Upgrades Eli Lilly to Buy - marketscreener.com

Berenberg Upgrades Eli Lilly to Buy marketscreener.com

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial - Eli Lilly

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Eli Lilly

Lilly’s GLP-1 Windfall to Fund Push Into Women’s Health - Bloomberg.com

Lilly’s GLP-1 Windfall to Fund Push Into Women’s Health Bloomberg.com

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? - Yahoo Finance

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? Yahoo Finance

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market - PR Newswire

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market PR Newswire

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases - Eli Lilly

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases Eli Lilly

Ginkgo Bioworks And Eli Lilly And Company Enter Partnership To Integrate Ginkgo Datapoints With Lilly TuneLab - marketscreener.com

Ginkgo Bioworks And Eli Lilly And Company Enter Partnership To Integrate Ginkgo Datapoints With Lilly TuneLab marketscreener.com

Eli Lilly launches oral weight-loss drug Foundayo in UK - Reuters

Eli Lilly launches oral weight-loss drug Foundayo in UK Reuters

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - PR Newswire

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress PR Newswire

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause - Eli Lilly

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause Eli Lilly

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - Eli Lilly

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Eli Lilly

Lilly announces three acquisitions to build infectious disease portfolio - Eli Lilly

Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly

Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars - Yahoo Finance

Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars Yahoo Finance

Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference - PR Newswire

Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference PR Newswire

/C O R R E C T I O N -- Eli Lilly and Company/ - PR Newswire

/C O R R E C T I O N -- Eli Lilly and Company/ PR Newswire

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - Eli Lilly

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - Eli Lilly

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly

Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits - Pharmaceutical Technology

Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits Pharmaceutical Technology

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide - BioPharma Dive

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide BioPharma Dive

In the US, Wells Fargo reports better margin trends, Berenberg upgrades Eli Lilly - UA.NEWS

In the US, Wells Fargo reports better margin trends, Berenberg upgrades Eli Lilly UA.NEWS

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market? - Yahoo Finance

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market? Yahoo Finance

Eli Lilly takes aim at illicit market for its experimental weight-loss drug - CBS News

Eli Lilly takes aim at illicit market for its experimental weight-loss drug CBS News

Novo Nordisk says it’s suing Eli Lilly, accusing it of false advertising - NBC News

Novo Nordisk says it’s suing Eli Lilly, accusing it of false advertising NBC News

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - Eli Lilly

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility Eli Lilly

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study - PR Newswire

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study PR Newswire

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines - Eli Lilly

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines Eli Lilly

Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? - STAT

Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? STAT